Vilya aims to leverage its proprietary platform to focus on previously difficult-to-drug therapeutic targets. The platform, which is powered by machine learning, taps into uncharted chemical space to design molecular structures with enhanced drug-like properties that range in size between small molecules and antibodies.

The USA-based company launched in August 2022 with $50 million in committed Series A financing led by ARCH Venture Partners.